This multicenter prospective observational study aims to evaluate the impact of iron chelation therapy (Exjade) on relapse rates in patients with acute myeloblastic leukemia (AML) and myelodysplastic syndrome (MDS) following allo-HSCT. The study is significant as it addresses a common complication (iron overload) in this patient population, potentially enhancing patient outcomes and survival rates. The findings could position Exjade favorably in the market, especially if a positive correlation between iron chelation and improved relapse-free survival is established. Given the competitive landscape of hematological malignancies, successful outcomes may lead to increased adoption of Exjade in clinical practice, influencing market dynamics and necessitating diligence in monitoring competitor responses.